Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights (GlobeNewswire) - Oct 20, 2022 - "During the remainder of 2022, the Company expects to accomplish the following key business objectives: (i) ReSPECT-GBM Phase 2 clinical trial initiation; (ii) Present updated data from the ReSPECT-GBM and ReSPECT-LM trials at the Society for Neuro-Oncology (SNO) Annual Meeting and Education Day, November 17-20, 2022; (iii) Complete Cohort 2 of ReSPECT-LM Phase 1/2a dose escalation trial; (iv) Submit an Investigational New Drug (IND) application to the FDA for the study of 186RNL in patients with pediatric brain cancer (ReSPECT-PBC), ependymoma and high-grade glioma."
IND • P1 data • Trial status • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor
|